NanoString Technologies, Inc. (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. The company was founded by Krassen Dimitrov, Amber Ratcliffe, and Dwayne Dunaway in 2003, and is based in Seattle, Washington. NanoString's "nCounter Analysis System" is based on a digital molecular barcoding technology invented by Dimitrov and Dunaway in Leroy Hood's lab at the Institute for Systems Biology (ISB), and became commercially available in 2008. NanoString received a CE-mark designation for selling the Prosigna™ Breast Cancer Prognostic Gene Signature Assay (PAM50-based breast cancer test) in Israel and EU in September 2012, and in September 2013, NanoString received FDA 510(k) clearance for Prosigna.